| Print
SANDOZ GROUP N (SDZ)
Open
69.00 CHF
Previous close
68.52 CHF
Trade high
70.42 CHF
Volume
1,035,480
Year high
75.90 CHF
Year low
46.77 CHF
Dividend yield
1.17%
Market capitalisation
30.29 bn CHF
P/E ratio
55.77
ISIN
CH1243598427
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Share price
Company profile
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 30 assets in its pipeline.